keyword
MENU ▼
Read by QxMD icon Read
search

Oral chemotherapy

keyword
https://www.readbyqxmd.com/read/28817826/the-safety-and-efficacy-of-the-s1-temozolomide-regimen-in-patients-with-metastatic-neuroendocrine-tumors
#1
Jiuda Zhao, Hong Zhao, Yihebali Chi
<br><br>Purpose Both capecitabine alone and capecitabine in combination with temozolomide have activities against neuroendocrine tumors (NETs). However, the role of S-1 in NETs is still unknown. We performed a study to evaluate the safety and efficacy of the S-1 plus temozolomide (STEM) regimen in patients with locally advanced or metastatic NETs. Methods A retrospective review was conducted in 20 patients with locally advanced or metastatic NETs treated with the STEM regimen. Of the patients, 15 (75...
August 17, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28816958/effective-apatinib-treatment-of-pleomorphic-liposarcoma-a-case-report
#2
Peng Yan, Mei-Li Sun, Yu-Ping Sun, Chuan-Yong Liu
RATIONALE: Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. PATIENT CONCERNS: We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy. DIAGNOSES: The patient was diagnosed as having PLS by biopsy. INTERVENTIONS: After a failed chemotherapy, apatinib started to be taken orally 425 mg per day...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28815259/-safety-and-efficacy-of-ultrasound-hyperthermia-combined-with-chemotherapy-and-radical-operation-for-advanced-oral-squamous-cell-carcinoma
#3
Cui-Ling Shao, Qian-Wei Zhuang, Jian Meng, Wei Guo, Guo-Xin Ren
PURPOSE: To explore the safety and efficacy of ultrasound hyperthermia combined with chemotherapy and radical operation for advanced oral squamous cell carcinoma (OSCC). METHODS: Nine patients who had definite pathological diagnosis were enrolled in this clinical trail from 2015 to 2016. All patients underwent ultrasound hyperthermia combined with chemotherapy before radical operation. The treatment regime was as follows: Docetaxel and cisplatin (75mg/m(2)) used on the first day, fluorouracil (750 mg/m(2)) infused from 1st to 5th day...
April 2017: Shanghai Kou Qiang Yi Xue, Shanghai Journal of Stomatology
https://www.readbyqxmd.com/read/28815025/oesophageal-candidiasis-and-squamous-cell-cancer-in-patients-with-gain-of-function-stat1-gene-mutation
#4
Sara Koo, Deepak Kejariwal, Tariq Al-Shehri, Anjan Dhar, Desa Lilic
BACKGROUND: Oesophageal candidiasis is a common, usually self-limiting opportunistic infection, but long-term infection with Candida is known to predispose to oral and oesophageal squamous cell cancer (SCC). Permissive factors that lead to immune deficiencies can underlie persistent or recurring candidiasis, called chronic mucocutaneous candidiasis (CMC). Secondary immune deficiencies are most often due to human immunodeficiency virus (HIV) infection, antibiotic use and immunosuppressive treatment (steroids, chemotherapy)...
August 2017: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/28814275/randomized-study-comparing-full-dose-monotherapy-s-1-followed-by-irinotecan-and-reduced-dose-combination-therapy-s-1-oxaliplatin-followed-by-s-1-irinotecan-as-initial-therapy-for-older-patients-with-metastatic-colorectal-cancer-nordic-9
#5
Stine Braendegaard Winther, Pia Österlund, Åke Berglund, Bengt Glimelius, Camilla Qvortrup, Halfdan Sorbye, Per Pfeiffer
BACKGROUND: Metastatic colorectal cancer (mCRC) is a disease of older age, but there is a relative lack of knowledge about effects of chemotherapy in older patients as they are under-represented in clinical trials. Little data can guide whether the strategy in older mCRC patients should be a sequential full-dose monotherapy chemotherapy approach or a dose-reduced combination chemotherapy approach. The oral 5FU prodrug S-1 seems to have less side effects than capecitabine and should be an optimal drug for older patients, but few data are available...
August 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28811898/lentinula-edodes-mycelia-extract-plus-adjuvant-chemotherapy-for-breast-cancer-patients-results-of-a-randomized-study-on-host-quality-of-life-and-immune-function-improvement
#6
Yukiko Nagashima, Shigehumi Yoshino, Shigeru Yamamoto, Noriko Maeda, Tatsuya Azumi, Yoshifumi Komoike, Kiyotaka Okuno, Tsutomu Iwasa, Junji Tsurutani, Kazuhiko Nakagawa, Oka Masaaki, Nagano Hiroaki
Anthracycline-based chemotherapies for breast cancer are known to adversely affect patients' quality of life (QOL) and immune function. For that reason, adjuvants that improve those impairments are required. A randomized double-blind study was conducted to evaluate the effectiveness of Lentinula edodes mycelia extract (LEM), which is an oral biological response modifier (BRM) medicine for cancer patients as such an adjuvant. A total of 47 breast cancer patients who were scheduled to receive postoperative adjuvant anthracycline-based chemotherapy, i...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28811720/endoscopic-occlusion-with-silicone-spigots-for-the-closure-of-refractory-esophago-bronchiole-fistula-after-esophagectomy
#7
Masaya Uesato, Tsuguaki Kono, Yasunori Akutsu, Kentarou Murakami, Akiko Kagaya, Yorihiko Muto, Akira Nakano, Mizuho Aikawa, Tomohide Tamachi, Hiroyuki Amagai, Takahiro Arasawa, Yasuhide Muto, Hisahiro Matsubara
A 65-year-old man with cT1bN0M0 stage I middle thoracic esophageal cancer underwent subtotal esophagectomy and gastric tube reconstruction through the posterior mediastinal route after preoperative carbon-ion radiotherapy and chemotherapy in a clinical trial. Anastomotic leakage occurred, but it spontaneously improved. At six months after the operation, he was rehospitalized with a cough and dysphagia. An esophago-bronchiole fistula and stenosis of the gastric tube were observed. He first underwent stent placement in the gastric tube...
July 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28810913/selinexor-kpt-330-demonstrates-anti-tumor-efficacy-in-preclinical-models-of-triple-negative-breast-cancer
#8
Natalia Paez Arango, Erkan Yuca, Ming Zhao, Kurt W Evans, Stephen Scott, Charissa Kim, Ana Maria Gonzalez-Angulo, Filip Janku, Naoto T Ueno, Debu Tripathy, Argun Akcakanat, Aung Naing, Funda Meric-Bernstam
BACKGROUND: Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative breast cancer (TNBC), we sought to determine the antitumor effects of selinexor in vitro and in vivo. METHODS: Twenty-six breast cancer cell lines of different breast cancer subtypes were treated with selinexor in vitro. Cell proliferation assays were used to measure the half-maximal inhibitory concentration (IC50) and to test the effects in combination with chemotherapy...
August 15, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28809036/clinical-investigation-of-38-cases-of-oral-mucosal-melanoma-a-multicentre-retrospective-analysis-in-japan
#9
Shin-Ichi Yamada, Hiroshi Kurita, Takahiro Kamata, Tadaaki Kirita, Michihiro Ueda, Tetsuro Yamashita, Yoshihide Ota, Mitsunobu Otsuru, Nobuhiro Yamakawa, Masaya Okura, Tomonao Aikawa, Souichi Yanamoto, Masahiro Umeda
BACKGROUND/OBJECTIVES: The aim of the present study was to investigate treatment modalities and outcomes in oral mucosal melanoma. METHODS: The clinical and pathological data of 38 consecutive patients with oral mucosal melanoma were retrospectively analyzed. Patients' characteristics were analyzed and overall survival (OS) rates were calculated. RESULTS: Sixteen patients had stage III (42%), 19 IVA (50%), and three had stage IVC (8%) disease...
August 15, 2017: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/28808915/cost-effectiveness-of-posaconazole-tablets-for-invasive-fungal-infections-prevention-in-acute-myelogenous-leukemia-or-myelodysplastic-syndrome-patients-in-spain
#10
Rafael Cámara, Irmina Gozalbo, Manuel Jurado, Jaime Sanz, Belén Aragón, Santiago Grau
INTRODUCTION: Posaconazole is superior to fluconazole (FLU) and itraconazole (ITRA) in the prevention of invasive fungal diseases (IFDs) in neutropenic patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). A new tablet formulation of posaconazole with improved pharmacokinetic and pharmacodynamic properties compared to posaconazole oral solution has recently been approved. The objective of this study is to estimate the cost-effectiveness of the newly developed posaconazole tablets versus FLU oral suspension or ITRA oral solution for preventing IFDs in high-risk neutropenic patients with AML or MDS and from the perspective of the Spanish National Health System (NHS)...
August 14, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28807749/high-dose-rate-interstitial-brachytherapy-boost-in-inoperable-locally-advanced-tongue-carcinoma
#11
Miguel Angel Santos, Jose Luis Guinot, Maria Isabel Tortajada, Paula Santamaría, Valentin Campo, Laura Oliver, Marina Peña, Leoncio Arribas
PURPOSE: Locally advanced tongue carcinomas (LATCs) in inoperable lesions are managed with external beam radiation therapy (EBRT) and chemotherapy. In our institution, the boost to the gross tumor volume is delivered with high-dose-rate brachytherapy (HDR-BT) after EBRT. We review the outcome of these patients when HDR-BT is added as a boost. METHODS AND MATERIALS: From May 2000 to December 2014, a total of 24 patients with LATC, nonsurgical oral tongue, and base of tongue carcinomas were treated with EBRT and with interstitial plastic tubes for brachytherapy; median dose was 18-24 Gy in 6-8 fractions after 50-60 Gy of EBRT...
August 11, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28800861/ipatasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line-therapy-for-metastatic-triple-negative-breast-cancer-lotus-a-multicentre-randomised-double-blind-placebo-controlled-phase-2-trial
#12
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga
BACKGROUND: The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer. METHODS: In this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium...
August 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28797467/outcomes-of-oral-cavity-cancer-patients-treated-with-surgery-followed-by-postoperative-intensity-modulated-radiation-therapy
#13
Sean R Quinlan-Davidson, Abdallah S R Mohamed, Jeffrey N Myers, Gary B Gunn, Faye M Johnson, Heath Skinner, Beth M Beadle, Ann M Gillenwater, Jack Phan, Steven J Frank, William N William, Andrew J Wong, Stephen Y Lai, Clifton D Fuller, William H Morrison, David I Rosenthal, Adam S Garden
OBJECTIVES: Although treatment paradigms have not changed significantly, radiotherapy, surgery, and imaging techniques have improved, leading us to investigate oncologic and survival outcomes for oral cavity squamous cell cancer (OCSCC) patients treated with surgery followed by postoperative IMRT. MATERIAL AND METHODS: Records of patients with pathological diagnosis of OCSCC treated between 2000 and 2012 were retrospectively reviewed. Patients' demographic, disease, and treatment criteria were extracted...
September 2017: Oral Oncology
https://www.readbyqxmd.com/read/28797451/post-operative-therapy-following-transoral-robotic-surgery-for-unknown-primary-cancers-of-the-head-and-neck
#14
Sapna A Patel, Aarthi Parvathaneni, Upendra Parvathaneni, Jeffrey J Houlton, Ron J Karni, Jay J Liao, Neal D Futran, Eduardo Méndez
OBJECTIVES: Our primary objective is to describe the post- operative management in patients with an unknown primary squamous cell carcinoma of the head and neck (HNSCC) treated with trans-oral robotic surgery (TORS). MATERIALS & METHODS: We conducted a retrospective multi-institutional case series including all patients diagnosed with an unknown primary HNSCC who underwent TORS to identify the primary site from January 1, 2010 to June 30, 2016. We excluded those with recurrent disease, ≤6months of follow up from TORS, previous history of radiation therapy (RT) to the head and neck, or evidence of primary tumor site based on previous biopsies...
September 2017: Oral Oncology
https://www.readbyqxmd.com/read/28794695/water-filtered-infrared-a-wira-overcomes-swallowing-disorders-and-hypersalivation-a-case-report
#15
Gerd Hoffmann
Case description: A patient with a Barrett oesophageal carcinoma and a resection of the oesophagus with gastric pull-up developed swallowing disorders 6 years and 2 months after the operation. Within 1 year and 7 months two recurrences of the tumor at the anastomosis were found and treated with combined chemoradiotherapy or chemotherapy respectively. 7 years and 9 months after the operation local tumor masses and destruction were present with no ability to orally drink or eat (full feeding by jejunal PEG tube): quality of life was poor, as saliva and mucus were very viscous (pulling filaments) and could not be swallowed and had to be spat out throughout the day and night resulting in short periods of sleep (awaking from the necessity to spit out)...
2017: German Medical Science: GMS E-journal
https://www.readbyqxmd.com/read/28794362/synchronous-duodenal-cancer-and-lung-cancer-harboring-an-epidermal-growth-factor-receptor-mutation-treated-with-erlotinib-and-oral-fluoropyrimidine
#16
Norimichi Akiyama, Masato Karayama, Moriya Iwaizumi, Yukiko Kusama, Masato Kono, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Takafumi Suda
Chemotherapy for multiple primary cancers is challenging. We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. A 78-year-old woman with advanced EGFR-mutated lung adenocarcinoma was simultaneously diagnosed with duodenal adenocarcinoma. After the treatment with erlotinib, the lung cancer responded well, but her duodenal cancer showed no response. S-1 was added to erlotinib, and the duodenal cancer demonstrated a good response with tolerable toxicities...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28790262/-determination-of-the-effect-of-aprepitant-and-fosaprepitant-for-nausea-in-patients-with-oral-cancer-receiving-combination-chemotherapy-with-tpf
#17
Kimio Uchiyama, Manabu Yamada, Yuusuke Shiiba, Shingo Kasazaki, Kenichirou Suga, Hiroshi Iwabuchi, Seiji Asoda, Keita Uehara
The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF).The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10).The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0...
July 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28789573/the-protective-effect-of-fish-oil-against-cisplatin-induced-eye-damage-in-rat
#18
Burcu Gul Baykalir, Osman Ciftci, Aslı Cetin, Nese Basak Turkmen
Ocular toxicity induced by anticancer chemotherapy is not uncommon, but underestimated and under-reported. Visual changes have been attributed to a number of chemotherapeutic agents in humans. Cisplatin (CP), a heavy metal compound, is used in the treatment of many types of tumors. CP is known to produce non-specific blurred vision, papilledema and optic neuritis for high doses as well as cumulative dose regimens. The aim of this study was to investigate the possible beneficial effects of fish oil (FO) on eye tissue oxidative status and histological alterations against CP-induced in the rats...
August 8, 2017: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/28782644/dmapt-inhibits-nf-%C3%AE%C2%BAb-activity-and-increases-sensitivity-of-prostate-cancer-cells-to-x-rays-in-vitro-and-in-tumor-xenografts-in-vivo
#19
Marc S Mendonca, William T Turchan, Melanie E Alpuche, Christopher N Watson, Neil C Estabrook, Helen Chin-Sinex, Jeremy B Shapiro, Imade E Imasuen-Williams, Gabriel Rangel, David P Gilley, Nazmul Huda, Peter A Crooks, Ronald H Shapiro
Constitutive activation of the pro-survival transcription factor NF-κB has been associated with resistance to both chemotherapy and radiation therapy in many human cancers, including prostate cancer. Our lab and others have demonstrated that the natural product parthenolide can inhibit NF-κB activity and sensitize PC-3 prostate cancers cells to X-rays in vitro; however, parthenolide has poor bioavailability in vivo and therefore has little clinical utility in this regard. We show here that treatment of PC-3 and DU145 human prostate cancer cells with dimethylaminoparthenolide (DMAPT), a parthenolide derivative with increased bioavailability, inhibits constitutive and radiation-induced NF-κB binding activity and slows prostate cancer cell growth...
August 3, 2017: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/28782476/a-case-of-capecitabine-induced-hyperammonemia-in-a-patient-with-colon-cancer
#20
Wentong Fang, Yuanyuan Fu, Ji-Fu Wei
BACKGROUND: Hyperammonemia is an infrequent adverse drug reaction (ADR) of chemotherapy. A few cases of 5-fluorouracil (5-FU) related hyperammonemia have been reported. OBJECTIVE: However, hyperammonemia induced by capecitabine, an oral prodrug of 5-FU, has not been reported till date. A patient with colon cancer was treated with CapeOx(oxaliplatin 200mg, day 1; capecitabine 1.5g bid, days 1-14). On the fifth day of first cycle chemotherapy, she developed hyperammonemia(240 μmol/L) and psychiatric symptoms...
August 7, 2017: Current Drug Safety
keyword
keyword
77578
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"